PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18652825-7 2008 A cotreatment of HT29 cells with a NFkappaB inhibitor (parthenolide) significantly inhibited the TSA-induced cellular levels of acetyl NFkappaB p65 and abolished the stimulation of STC1 gene expression. parthenolide 55-67 stanniocalcin 1 Homo sapiens 181-185 18652825-8 2008 ChIP assay also demonstrated that TSA treatment increased while TSA/parthenolide cotreatment decreased NFkappaB p65 binding to STC1 gene promoter. parthenolide 68-80 stanniocalcin 1 Homo sapiens 127-131 18652825-11 2008 Consistent with the STC1mRNA expression data, TSA/parthenolide cotreatment also significantly inhibited the TSA-induced STC1 promoter-driven luciferase activity. parthenolide 50-62 stanniocalcin 1 Homo sapiens 20-24 18652825-11 2008 Consistent with the STC1mRNA expression data, TSA/parthenolide cotreatment also significantly inhibited the TSA-induced STC1 promoter-driven luciferase activity. parthenolide 50-62 stanniocalcin 1 Homo sapiens 120-124